Latest news with #ClareonPanOptixPro
Yahoo
7 hours ago
- Business
- Yahoo
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡ TORONTO, June 20, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,§,§§,¶,¶¶ "As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D," said Rob Scott, VP, Intraocular Devices, R&D, Alcon. "Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL."1-3,20,21,*,**,‡‡,‖,Ω "PanOptix has been a cornerstone of my cataract practice for eight years," said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. "These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile25, ∂and a happy patient with greater spectacle independence.23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients." PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe® preloaded delivery system and as well as with the Clareon Monarch® IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. About Clareon PanOptix Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at *PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). **Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. †For feasible diffractive optics of up to pentafocal design from Krackhardt et al. ††Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡Compared to Clareon PanOptix. ‡‡Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question "In the past 7 days, how often did you need to wear eyeglasses to see"? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ‖Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. ΩSeverity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome" and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. References Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Connect with us onFacebook LinkedIn View source version on Contacts Media Relations Jane Lee Cheung+1 289 290 2393 (Canada) Sign in to access your portfolio
National Post
7 hours ago
- Business
- National Post
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Article content Clareon PanOptix Pro has half the light scatter of Clareon PanOptix 1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics 1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast 1,††,‡ Article content TORONTO — Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients inCanada. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL. 1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics. 1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. 1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. 10-13,§,§§,¶,¶¶ 'Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.' Article content 'As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,' said Rob Scott, VP, Intraocular Devices, R&D, Alcon. 'Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. 1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL.' 1-3,20,21,*,**,‡‡,‖,Ω 'PanOptix has been a cornerstone of my cataract practice for eight years,' said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. 'These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile 25, ∂ and a happy patient with greater spectacle independence. 23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible ‡,‡‡, empowering both my practice and my patients.' Article content PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe ® preloaded delivery system and as well as with the Clareon Monarch ® IV delivery system in early 2026. 22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering. 22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. Article content About Clareon PanOptix Pro Article content The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at Article content About Alcon Article content Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at Article content * PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). ** Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. † For feasible diffractive optics of up to pentafocal design from Krackhardt et al. †† Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡ Compared to Clareon PanOptix. ‡‡ Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question 'In the past 7 days, how often did you need to wear eyeglasses to see'? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op 'Given your vision today, if you had to do it all over, would you have the same lenses implanted again?'; n=127. ‖ Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. Ω Severity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂ Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including 'very bothersome' and 'severe' visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. Article content References Article content Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Article content Article content Article content Article content Article content Contacts Article content Media Relations Article content Article content Article content Article content
Business Wire
8 hours ago
- Business
- Business Wire
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL. 1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics. 1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. 1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. 10-13,§,§§,¶,¶¶ "Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.' Share 'As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,' said Rob Scott, VP, Intraocular Devices, R&D, Alcon. 'Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. 1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL.' 1-3,20,21,*,**,‡‡,‖,Ω 'PanOptix has been a cornerstone of my cataract practice for eight years,' said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. 'These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile 25, ∂ and a happy patient with greater spectacle independence. 23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible ‡,‡‡, empowering both my practice and my patients.' PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe ® preloaded delivery system and as well as with the Clareon Monarch ® IV delivery system in early 2026. 22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering. 22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. About Clareon PanOptix Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at * PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). ** Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. † For feasible diffractive optics of up to pentafocal design from Krackhardt et al. †† Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡ Compared to Clareon PanOptix. ‡‡ Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question 'In the past 7 days, how often did you need to wear eyeglasses to see'? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ‖ Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. Ω Severity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂ Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome' and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. Expand References Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Yahoo
02-04-2025
- Business
- Yahoo
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world's leading trifocal IOL3-5,‡ GENEVA, April 02, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the highest reported light utilization of any trifocal IOL—and the lowest light scatter.1-3,6-10,§,** These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,† PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.1,2,11,12,**,°,Δ "As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix," said Rob Scott, VP, Intraocular Devices, R&D, Alcon. "Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,2,13-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL."3-5,‡ "PanOptix has been a game-changer in my practice, allowing me to reliably offer many of my patients complete freedom from glasses after cataract surgery," said Kerry Solomon, MD, Medical Director at Carolina Eyecare Physicians, LLC.11,20 "I was excited to learn that Alcon evolved this leading technology for more light utilization and less light scatter.1,2,* My early patient results with PanOptix Pro support that this advancement builds on the well-established performance of PanOptix." PanOptix Pro will be the first presbyopia-correcting IOL available in the U.S. from Alcon in the single-use Clareon AutonoMe® preloaded delivery system. PanOptix Pro will also be available for use with the Clareon Monarch® IV delivery system beginning in 2026.12 PanOptix Pro offers powers ranging from +6.0 through +30.0 diopters (in 0.5 diopter increments), +31.0 through +34.0 diopters (in 1.0 diopter increments), with a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.12 PanOptix Pro has been introduced to select practices across the U.S., with broad commercial availability in May. Additional markets will begin rollout in late 2025. For surgeons interested in more information on PanOptix Pro, visit or visit the Alcon Booth #1815 at the American Society of Cataract and Refractive Surgery annual meeting (Los Angeles, April 25-28). For patients interested in learning more about PanOptix Pro, visit About AlconAlcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About Clareon PanOptix ProThe Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Potential Side Effects: Due to the design of multifocal IOLs, there are some side effects that can be associated with the Clareon PanOptix Pro Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decreased ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog or in a dimly lit room after surgery, as compared to before surgery. *Compared to Clareon PanOptix. PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro has 94% light utilization (6% scatter light).†Based on bench-measured, average white-light modular transfer function (MTF) from 0 to 70 lp/mm at 3mm aperture, compared to PanOptix.‡Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof® IQ PanOptix through Q1, 2024.§Based on manufacturer reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.**Based on bench and vision simulator studies.°Based on data for AcrySof IQ PanOptix Trifocal IOL.ΔResponse to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. References Alcon data on file, 2025. REF-25218 Alcon data on file, 2015. REF-08546 Alcon data on file, 2024. REF-25221 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed March 2025. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed March 2025. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2): Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614-1617. doi:10.1177/154193120805201965. Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164. Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Connect with us onFacebook LinkedIn View source version on Contacts Investor Relations Daniel Cravens, Allen Trang+ 41 589 112 110 (Geneva)+ 1 817 615 2789 (Fort Worth) Media Relations Steven Smith+ 41 589 112 111 (Geneva)+ 1 817 551 8057 (Fort Worth) Sign in to access your portfolio
